Literature DB >> 22896026

The Canadian Early Arthritis Cohort (CATCH): patients with new-onset synovitis meeting the 2010 ACR/EULAR classification criteria but not the 1987 ACR classification criteria present with less severe disease activity.

Vivian P Bykerk1, Shahin Jamal, Gilles Boire, Carol A Hitchon, Boulos Haraoui, Janet E Pope, J Carter Thorne, Ye Sun, Edward C Keystone.   

Abstract

OBJECTIVE: Our objective was to describe characteristics of Canadian patients with early arthritis and examine differences between those fulfilling 1987 and 2010 rheumatoid arthritis (RA) classification criteria.
METHODS: The Canadian Early Arthritis Cohort (CATCH) is a national, multicenter, observational, prospective cohort of patients with early inflammatory arthritis, receiving usual care, recruited since 2007. Inclusion criteria include age > 16 years; symptom duration 6-52 weeks; swelling of ≥ 2 joints or ≥ 1 metacarpophalangeal/proximal interphalangeal joint; and 1 of rheumatoid factor ≥ 20 IU, positive anticitrullinated protein antibodies (ACPA), morning stiffness ≥ 45 min, response to nonsteroidal antiinflammatory drug, or positive metatarsophalangeal joint squeeze test. Data from patients enrolled to March 15, 2011, were analyzed.
RESULTS: In total, 1450 patients met the eligibility criteria (1187 were followed). At baseline, mean age was 53 ± 15 years, symptom duration was 6.1 ± 3.2 months, Disease Activity Score (DAS28) was 4.9 ± 1.6, Health Assessment Questionnaire-Disability Index was 1.0 ± 0.7. Forty-one percent (n = 450) of patients had moderate (3.2 < DAS28 ≤ 5.1) and 46% (n = 505) had high (DAS28 > 5.1) disease activity; 28% of those with baseline radiographs (n = 250/908) had radiographic evidence of erosions. ACPA status was available for 70% (n = 831) of patients; 55% (n = 453) tested positive. Sixty percent (n = 718) of patients were treated with methotrexate (MTX) initially. Of 612 patients without erosions, 63% and 83% fulfilled 1987 and 2010 RA classification criteria, respectively. Seventy-three percent (n = 166) of those who did not fulfill 1987 criteria were newly identified by the 2010 criteria. These patients had less severe disease and more were MTX-naive compared to those satisfying the 1987 criteria. Forty-seven percent of all patients achieved remission at 1 year.
CONCLUSION: Patients with early RA present with moderate high disease activity; < 50% achieve remission at 1 year, despite MTX treatment in the majority. The 2010 RA classification criteria identify more patients with RA who would previously have been designated as having undifferentiated disease. However, these patients have lower disease activity at the time of identification.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22896026     DOI: 10.3899/jrheum.120029

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  17 in total

1.  Identification of potential serum biomarkers for rheumatoid arthritis by high-resolution quantitative proteomic analysis.

Authors:  Yongjing Cheng; Yuling Chen; Xiaolin Sun; Yuhui Li; Cibo Huang; Haiteng Deng; Zhanguo Li
Journal:  Inflammation       Date:  2014-10       Impact factor: 4.092

2.  The new ACR/EULAR criteria for rheumatoid arthritis can identify patients with same disease activity but less damage by ultrasound.

Authors:  Sibel Zehra Aydın; Concepcion Castillo-Gallego; Jackie Nam; Jane Freeston; Sarah Horton; Richard J Wakefield; Paul Emery
Journal:  Eur J Rheumatol       Date:  2017-06-01

3.  Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients.

Authors:  J R Curtis; S Yang; L Chen; J E Pope; E C Keystone; B Haraoui; G Boire; J C Thorne; D Tin; C A Hitchon; C O Bingham; V P Bykerk
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-10       Impact factor: 4.794

4.  "From Where I Stand": using multiple anchors yields different benchmarks for meaningful improvement and worsening in the rheumatoid arthritis flare questionnaire (RA-FQ).

Authors:  Susan J Bartlett; Vivian P Bykerk; Orit Schieir; Marie-France Valois; Janet E Pope; Gilles Boire; Carol Hitchon; Glen Hazlewood; Louis Bessette; Edward Keystone; Carter Thorne; Diane Tin; Clifton O Bingham
Journal:  Qual Life Res       Date:  2022-09-08       Impact factor: 3.440

Review 5.  Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare Workshop.

Authors:  Vivian P Bykerk; Elisabeth Lie; Susan J Bartlett; Rieke Alten; Annelies Boonen; Robin Christensen; Daniel E Furst; Sarah Hewlett; Amye L Leong; Anne Lyddiatt; Lyn March; James E May; Pam Montie; Ana-Maria Orbai; Christoph Pohl; Marieke Scholte Voshaar; Thasia Woodworth; Clifton O Bingham; Ernest H Choy
Journal:  J Rheumatol       Date:  2014-03-01       Impact factor: 4.666

6.  Factors associated with time to diagnosis in early rheumatoid arthritis.

Authors:  Cheryl Barnabe; Juan Xiong; Janet E Pope; Gilles Boire; Carol Hitchon; Boulos Haraoui; J Carter Thorne; Diane Tin; Edward C Keystone; Vivian P Bykerk
Journal:  Rheumatol Int       Date:  2013-08-30       Impact factor: 2.631

7.  Comparison of the 1987 American College of Rheumatology and the 2010 American College of Rheumatology/European League against Rheumatism criteria for classification of rheumatoid arthritis in the Nurses' Health Study cohorts.

Authors:  Shanthini Kasturi; Barbara L Goldstein; Susan Malspeis; Elizabeth W Karlson; Karen H Costenbader
Journal:  Rheumatol Int       Date:  2013-09-24       Impact factor: 2.631

8.  Predictors of Influenza Vaccination in Early Rheumatoid Arthritis 2017-2021: Results From the Canadian Early Arthritis Cohort.

Authors:  Viviane Ta; Orit Schieir; Marie-France Valois; Ines Colmegna; Carol Hitchon; Louis Bessette; Glen Hazlewood; Carter Thorne; Janet Pope; Gilles Boire; Diane Tin; Edward C Keystone; Vivian P Bykerk; Susan J Bartlett
Journal:  ACR Open Rheumatol       Date:  2022-03-29

Review 9.  Feasibility and Domain Validation of Rheumatoid Arthritis (RA) Flare Core Domain Set: Report of the OMERACT 2014 RA Flare Group Plenary.

Authors:  Susan J Bartlett; Vivian P Bykerk; Roxanne Cooksey; Ernest H Choy; Rieke Alten; Robin Christensen; Daniel E Furst; Francis Guillemin; Serena Halls; Sarah Hewlett; Amye L Leong; Anne Lyddiatt; Lyn March; Pamela Montie; Ana Maria Orbai; Christoph Pohl; Marieke Scholte Voshaar; Thasia G Woodworth; Clifton O Bingham
Journal:  J Rheumatol       Date:  2015-02-15       Impact factor: 4.666

10.  Expression of the myeloid inhibitory receptor CLEC12A correlates with disease activity and cytokines in early rheumatoid arthritis.

Authors:  Myriam Vaillancourt; Philippe Desaulniers; Guillaume Paré; Nathalie Pagé; Asmaa Lachhab; Anthony Kerever; Anne-Sophie Julien; Nathalie Amiable; Martin Pelletier; Philippe A Tessier; Louis Bessette; Laëtitia Michou; Paul R Fortin; Maria J Fernandes
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.